AzTrials
AzTrials

Coronary Artery DiseaseFFRicECGNCT03985241

Functional Assessment of Myocardial Ischemia by Intracoronary Electrocardiogram

A study testing Functional Assessment of Myocardial Ischemia by icECG in people with Coronary Artery Disease and Stable Angina, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In patients with chronic stable coronary artery disease (CAD), percutaneous coronary intervention (PCI) targets hemodynamically significant coronary lesions, i.e., those thought to cause inducible ischemia. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Functional Assessment of Myocardial Ischemia by icECG
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteSwitzerland
Study dates
3 Dec 2016to 13 Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age > 18 years
  • Referred for elective coronary angiography
  • Written informed consent to participate in the study

Who cannot join

  • Acute coronary syndrome
  • Severe aortic stenosis
  • Acute congestive heart failure NYHA III-IV
  • Prior myocardial infarction in the vascular territory undergoing pressure measurements
  • Presence of left bundle branch block, non-sinus rhythm or paced rhythm in resting ECG
  • Coronary anatomy unsuitable for coronary pressure measurements
Show all 9Show fewer
  • Severe pulmonary, renal or hepatic disease
  • Contraindication to inotropic stress
  • Women of childbearing age

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University Hospital Inselspital, Bern

    Bern

Other trials in Switzerland

About this study

In patients with chronic stable coronary artery disease (CAD), percutaneous coronary intervention (PCI) targets hemodynamically significant coronary lesions, i.e., those thought to cause inducible ischemia. The hemodynamic severity of a coronary stenosis increases with its tightness and with the myocardial mass of viable myocardium downstream of the stenosis.

Compared to the traditional anatomic angiographic approach, assessment of functional relevance by fractional flow reserve (FFR) during coronary angiography has been suggested to improve patient outcomes. Fractional flow reserve (FFR) is based on determination of the coronary perfusion pressure downstream of a stenosis during pharmacologic hyperemia. However, FFR relies on oversimplified physiologic concepts, which limits its usefulness in defining a true ischemic threshold. Furthermore, visual angiographic assessment continues to dominate the treatment decisions for intermediate coronary lesions.

Conversely, the intracoronary ECG (icECG) provides an inexpensive, sensitive and direct measure of myocardial ischemia. The icECG is easily acquired by attaching a reusable alligator clamp to a conventional angioplasty guidewire (at one tenth the price of a pressure sensor guidewire). The coronary guide wire positioned downstream of a coronary stenosis then acts as the exploring electrode. During pharmacologic stress, the icECG can provide direct evidence for regional myocardial ischemia to define the ischemic threshold in different types of coronary artery disease.

Read the detailed description

INVASIVE PRESSURE-DERIVED INDICES OF STENOSIS SEVERITY

In the setting of stable coronary artery disease (CAD), PCI or coronary artery bypass grafting (CABG) targets coronary lesions causing inducible myocardial ischemia. With the advancement of technology, the development of a coronary pressure guide wire enabled to reliably measure coronary perfusion pressure downstream of a stenosis and therefore trans-stenotic pressure gradients. On the basis of comparisons to noninvasive stress tests, the concept of fractional flow reserve (FFR) was introduced. FFR determines the ratio of mean distal coronary pressure and mean aortic pressure (the effective coronary perfusion pressure) during (pharmacologic) hyperemia. A FFR value of near 1 is then equivalent to a totally normal coronary artery, whereas a cutoff of 0.75-0.80 is commonly used to determine that PCI is warranted.

With FFR, pharmacologic hyperemia is mandatory to induce minimal and constant myocardial resistance, which is the basis to directly relate coronary pressure and flow.In contrast, the recently introduced concept of the instantaneous wave-free ratio (iFR) claims to obviate the need for administration of pharmacologic stress. Instead, coronary pressure is analyzed at rest and during part of coronary diastole, when myocardial resistance is thought to be naturally constant and minimal (the so called wave-free period).

LIMITATIONS OF PRESSURE-DERIVED INDICES OF STENOSIS SEVERITY IN DEFINING THE ISCHEMIC THRESHOLD

A major limitation of pressure-derived indices of stenosis severity is related to the assumption of oversimplified physiologic concepts. Clinically, the diagnostic accuracy of FFR is restricted in three scenarios. Firstly, the pressure gradient evaluated by FFR is critically dependent on the magnitude of resistance offered by the microcirculation. With microvascular dysfunction, microvascular resistance remains inadequately high during pharmacologic hyperemia, meaning that the pressure gradient across the stenosis does not reflect the epicardial stenosis severity (overestimation of FFR).

Secondly, with a focal stenosis, but well-preserved microvascular function and minimal diffuse atherosclerosis, hyperemic coronary flow (although reduced) may still be above the ischemic threshold, although the pressure gradient suggests otherwise. Thirdly, with severe diffuse coronary atherosclerosis, coronary flow may be reduced below the ischemic threshold, but with only an insignificant fall in the hyperemic pressure gradient (FFR). In summary, although FFR claims otherwise, the ischemic threshold set by FFR is unreliable in a significant proportion of pathophysiological and clinical scenarios.

DIRECT ASSESSMENT OF REVERSIBLE MYOCARDIAL ISCHEMIA BY INTRACORONARY ELECTROCARDIOGRAM

The electrocardiogram (ECG) is an indispensable tool in the diagnosis of myocardial ischemia. The commonly used surface ECG is however limited especially in detecting short-lasting, or minor myocardial ischemia. Furthermore, ischemia in the territory of the left circumflex coronary artery is often undetected. Conversely, due to its close vicinity to the myocardium, the intracoronary ECG (icECG) is much more sensitive in detecting acute myocardial ischemia. The icECG is obtained by attaching a reusable alligator clamp to a coronary guidewire. With the guidewire positioned in a coronary artery, the derived (pseudo)unipolar icECG reflects local epicardial ECG.

The value of the icECG was first shown by Friedman et al. Unipolar icECG was recorded during balloon dilatation of coronary stenosis from the guidewire positioned across the stenosis to be dilated. Ischemic changes in icECG was observed in 72% of stenoses dilated. In the cases with no ischemic changes, either a prior myocardial infarction in the territory undergoing balloon dilatation or angiographic collaterals were present, consistent with the notion that ischemia was not inducible in nonviable myocardium or prevented by sufficient collaterals. Of note, ST changes in the surface ECG were seen in only 31% of cases.

With acute and complete coronary occlusion, perfusion to the dependent territory is usually severely reduced which explains the frequent occurrence of icECG changes. However, the usefulness of the icECG has also been shown with partial coronary occlusion. Experimentally, Battler et al. demonstrated that during a partial stenosis producing only mild regional dysfunction, significant ST segment changes in regional epicardial ECG could be observed after 2-3 minutes. Clinically, Hishikari et al. showed in patients with non-ST-segment elevation myocardial infarction (NSTEMI) that ST-segment-elevation in the icECG (icECG-STE) was observed in 27.6% of patients before PCI and was more common with LCX culprit lesions. Furthermore, in multivariate analysis, icECG-STE predicted greater peak values of troponin levels, consistent with greater myocardial injury. Similarly, but in patients undergoing elective PCI, Uetani et al. showed that icECG provided a useful method to predict post-procedural myocardial injury.

With regard to detection of inducible ischemia by pharmacologic (vasodilator) stress, Balian et al. compared STsegment shift in the icECG (IST) during intravenous adenosine infusion with FFR in 48 patients. 81% of patients with an FFR ≤0.80 showed IST during adenosine infusion, while 14% had IST with an FFR >0.80. As a major limitation, the study compared icECG findings only with FFR and therefore, the mechanism of discordant results remained unclear. Furthermore, the choice of the pharmacologic stressor was questionable: the perfusion abnormalities induced by adenosine are the result of flow heterogeneity, in contrast to exercise (or inotropic pharmacologic stress, eg. dobutamine), where the perfusion abnormalities are the result of myocardial ischemia (detectable by the electrocardiogram).

Thus, the goal of this study is to test the accuracy of intracoronary (ic) ECG during pharmacologic inotropic stress (i.e. Imitation of daily physical activity) to determine significant coronary lesions in comparison with established physiologic indices (fractional flow reserve (FFR), instantaneous wave-free ratio (iFR)) as well as with quantitatively determined percent diameter stenosis (%S) using biplane coronary angiography.

Being tested
Functional Assessment of Myocardial Ischemia by icECG
Keywords
Intracoronary Electrocardiogram, Fractional Flow Reserve, Collateral Flow Index, Dobutamine
Medical subject headings
Coronary Artery Disease, Angina, Stable, Coronary Stenosis, Ischemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Functional Assessment of Myocardial Ischemia by icECGDiagnostic test

Study groups in NCT03985241
Study groupRoleWhat they receive
Functional Assessment of Myocardial Ischemia by icECGExperimentalEvaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
Receives: Diagnostic Test: Functional Assessment of Myocardial Ischemia by icECG

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intracoronary Electrocardiogram ST-Segment Shift

    Change in intracoronary ST-segment shift from baseline to hyperemia, measured at the J-Point in mV

    Measured: Measured at maximal heart frequency (=~6min after begin dobutamine)

Secondary outcomes (4)
  1. Percent Diameter Stenosis

    Assessment of percent diameter Stenosis using quantitative coronary angiography; comparison with icECG

    Measured: During diagnostic angiography at the beginning of the coronary angiography

  2. Fractional Flow Reserve

    FFR during steady-state hyperemia; comparison with icECG

    Measured: Measured at maximal heart frequency (=~6min after begin dobutamine)

  3. Instantaneous wave-free ratio

    iFR at baseline; comparison with icECG

    Measured: Measured at baseline before inotropic stress

  4. Area at Risk

    Myocardial area at risk in percent using the Approach-Score and relation to intracoronary ECG ST-Segment shift

    Measured: Measured after the coronary angiography, expected to be on average after 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2019
  2. Study start3 Dec 2016
  3. Primary completion13 Dec 2019
  4. Study completion13 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03985241
Sponsor's protocol ID
2016-00726
Other IDs
2016
Acronym
FFRicECG
Status last verified
Dec 2019
First submitted
5 Jun 2019
Last updated
19 Dec 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Functional Assessment of Myocardial Ischemia by icECG in people with Coronary Artery Disease and Stable Angina, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intracoronary Electrocardiogram ST-Segment Shift (time frame: Measured at maximal heart frequency (=~6min after begin dobutamine)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in